Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RHI Magnesita Q1 sales fall, downside risks increase

(Sharecast News) - Refractory products supplier RHI Magnesita said both sales and margins had fallen in Q1 as downside risks to its FY25 trading outlook increased, driven by a weak outlook for H1 performance and rising global trade tensions, all of which could negatively affect end markets. RHI Magnesita said Q1 trading conditions "became more challenging", reflecting lower sales volumes, a continued decline in project business in the glass and non-ferrous metals sectors worldwide and lower pricing for cement and steel markets in India and the Middle East.

Underlying earnings margins were also lower, impacted by a combination of lower volumes in its high-margin project business, weaker finished goods pricing and higher cost of purchased raw material.

As a result of the demand backdrop, RHI stated it was continuing to operate its plants at lower levels of capacity utilisation compared to Q424, with fixed cost under-absorption further weighing on margins.

The FTSE 250-listed firm also noted that in response to higher unit costs, a price increase programme was now being implemented to restore margins over the remainder of the year, although it noted that securing increases was "likely to be more challenging" in the current market environment.

As of 1040 BST, RHI shares were down 5.71% at 3,059.60p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.